Last updated on May 2019

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer


Brief description of study

The purpose of this research study is to compare the efficacy and safety of EG12014 with Herceptin as neoadjuvant treatment for 12 weeks, followed by surgery and subsequent EG12014 or Herceptin adjuvant treatment for up to 12 months.

Clinical Study Identifier: NCT03433313

Find a site near you

Start Over

Detroit Clinical Research Center

Farmington Hills, MI United States
  Connect »

Rodrigo Botero SAS

Medellín, Colombia
  Connect »

Arkhangelsk Clinical Oncology Center

Arkhangel'sk, Russian Federation
  Connect »

Evimed, LLC

Chelyabinsk, Russian Federation
  Connect »

Sverdlovsk Regional Oncology Center

Ekaterinburg, Russian Federation
  Connect »

Siberian District Medical Center

Novosibirsk, Russian Federation
  Connect »

Clinical Oncology Center

Omsk, Russian Federation
  Connect »

Rostov Oncology Research Institute

Rostov-on-Don, Russian Federation
  Connect »

AV Medical Group

Saint Petersburg, Russian Federation
  Connect »

Clinic "Mart"

Saint Petersburg, Russian Federation
  Connect »

Leningrad Regional Oncology Center

Saint Petersburg, Russian Federation
  Connect »

Oncology Center of Moskovskiy District

Saint Petersburg, Russian Federation
  Connect »

Republican Oncology Center

Saransk, Russian Federation
  Connect »

Oncology Center #2

Sochi, Russian Federation
  Connect »

Regional Clinical Oncology Center

Veliky Novgorod, Russian Federation
  Connect »

The Oncology Centre

Durban, South Africa
  Connect »

Rodrigo Botero SAS

Medellín, Colombia
  Connect »